Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Chemic Laboratories Inc. and ASI today announced
establishment of a formal three year Joint Cooperation Agreement that will enable the two firms
to collaborate on a variety of Pharmaceutical and Biopharmaceutical client interests, primarily in
the...
read more
Friday, December 20, 2013
Following a successful inspection by the German health authorities in July 2013 ChemCon received the approval required to manufacture semi-solid pharmaceuticals (gels and creams for topical therapy) for human use. This was an important step for the ...
read more
Tuesday, December 05, 2017
Check-Cap has entered the next phase of its manufacturing collaboration with GE Healthcare.
read more
Wednesday, September 07, 2022
Charles River Laboratories International and Cure AP-4, a non-profit foundation dedicated to raising funds and awareness about Adapter-Protein 4 Hereditary Spastic Paraplegia (AP-4 HSP), have announced a manufacturing collaboration.
read more
Charles River Laboratories International Inc. announced a long-term solar energy contract to address the entirety of the Company’s North American electric power requirements with clean, renewable energy by 2023. Charles River and Duke Energy ...
read more
Wednesday, April 06, 2022
Charles River Laboratories International, Inc. has acquired Explora BioLabs Holdings, Inc., a provider of contract vivarium research services.
read more
Thursday, January 27, 2022
Charles River Laboratories International, Inc. has announced the expansion of their strategic partnership with Chicago, Illinois-based SAMDI Tech, Inc. Under the existing partnership, established in 2018, SAMDI Tech clients have access to Charles ...
read more
Thursday, January 12, 2023
Charles River Laboratories International, Inc. announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO) and biologics testing experience.
read more
Charles River has completed the previously announced acquisition of Cognate BioServices for approximately $875 million.
read more
Charles River Laboratories International, Inc. and Ziphius Vaccines, a biopharmaceutical company developing self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, announced an agreement to manufacture starting ...
read more
Wednesday, January 19, 2022
Charles River Laboratories International, Inc. and Valo Health, LLC announced the formation of a multiyear strategic partnership. This agreement will combine Valo’s Opal Computational Platform with Charles River’s drug discovery and development ...
read more
Wednesday, January 18, 2023
Charles River Laboratories International, Inc and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced a viral vector contract development and manufacturing organization...
read more
Charles River Laboratories International, Inc. and ASC Therapeutics announced they have agreed to manufacture ASC618, a second-generation gene therapy for hemophilia A.
read more
ChargePoint Technology has announced the appointment of Kieran Coulton as Chairman.
read more
Thursday, September 25, 2014
CEVEC Pharmaceuticals, the developer and licensor of the CAP® Technology today announced the extension of its CAP® Technology Business portfolio by offering cGMP compliant Contract Manufacturing Services.
CAP® derived clinical materials comprising ...
read more